Table 3 Summary of paper characteristics
From: Acceptability of an on-demand pericoital oral contraceptive pill: a systematic scoping review
Citation | Contraception | Contraceptive use | Study design | Study population and sample size | Location |
|---|---|---|---|---|---|
International | |||||
Festin et al. [10] | Pericoital oral pill (LNG 1.5 mg) | Mean monthly pill intake of 4.3–6.2 | Trial | Women, 18–45 yrs (n = 330) | Urban cities; Thailand, Brazil, Singapore, Hungary |
Africa | |||||
Both & Samuel [26] | ECP | Repeat ever use: 64% more than once, incl. 34% more than 10 times | Qualitative | Young people, 15–29 yrs (n = 66); Pharmacists (n = 8); stakeholders: (n = 3) | Urban city; Ethiopia |
Chin-Quee et al. [27] | Pericoital oral pill (LNG 1.5 mg) | Hypothetical use | Quantitative survey | Women, 18–49 yrs (n = 6162) | Urban cities; Kenya, Nigeria |
Chin-Quee et al. [28] | ECP | ECP was main contraceptive for 15% in Nairobi and 41% in Lagos | Quantitative survey | Women, 18–49 yrs (n = 1022) | Urban cities; Kenya, Nigeria |
Fourn et al. [29] | ECP | Repeat ever use: 1–3 times (15%); 4–10 times (4%) | Quantitative survey | Female university students, 16 + yrs (n = 570) | Urban city; Benin |
Morgan et al. [30] | ECP | Repeat use: 18–48% > monthly; 12–38% main contraception | Quantitative survey | Women, 15–49 yrs (n = 12,652) | Urban cities; Kenya, Nigeria |
Both [31] | ECP | Repeat use & main contraception | Qualitative | Young people, 18–29 yrs (n = 30) | Urban city; Ethiopia |
Ajayi et al. [32] | ECP; other postcoital strategy | Self-reported use of ECP as only modern contraceptive | Qualitative | Unmarried female university students, 17–28 yrs (n = 56) | Urban towns; Nigeria |
Darteh & Doku [33] | ECP | Repeat use: weekly (8%); monthly (25%); occasionally (63%) | Quantitative survey | Male and female university students (n = 571) | Urban city, Ghana |
Gure et al. [34] | ECP; other postcoital strategy | Hypothetical ECP use | Qualitative | Women, 18–53 yrs (n = 21); Pharmacists (n = 20); stakeholders: (n = 10) | Urban city; Somalia |
Hernandez et al. [35] | ECP; other postcoital strategy | Hypothetical ECP use | Qualitative | Women, 15–35 yrs (n = 169) | Urban, rural, university settings; DRC |
Rokicki & Merten [36] | ECP; other postcoital strategy | Repeat use & main contraception | Qualitative | Unmarried women, 18–24 yrs (n = 32) | Urban city; Ghana |
Nara et al. [37] | ECP; other postcoital strategy | Hypothetical ECP use | Qualitative | Refugee, 15–49 yrs (n = 57); Service providers/stakeholders (n = 11) | Urban city; Uganda |
Henry et al. [38] | ECP | Ever contraceptive users: 3% only ECP, 3% ECP + traditional; Recent ECP users: 51% used ECP in two months or more in a row | Quantitative survey | Women, 16–44 yrs (n = 3703) | Urban city; Ghana |
Kalamar et al. [39] | ECP | Repeat use & main contraception | Qualitative | Women, 18–34 yrs (n = 299); Men, 18–30 yrs (n = 75) | Urban cities; Ghana; Zambia |
McCann et al. [11] | Pericoital oral pill (LNG 1.5 mg) | Average peri-coital use 1.72 times/ month; 83% primary contraceptive | Intervention | Women, 18–49 yrs (n = 873) | Urban cities, Ghana |
Odwe et al. [12] | Pericoital oral pill (LNG 1.5 mg) | Average use of peri-coital pill of 1.3 times per month | Intervention | Women, 18–49 yrs (n = 768) | Urban & peri-urban areas; Kenya |
Americas | |||||
Brandao et al. [40] | ECP | N/A; provider perspectives | Qualitative | Pharmacists (n = 20) | Urban city, Brazil |
Provenzano-Castro et al. [41] | ECP | 4% used ECP as primary contraceptive | Quantitative survey | Male / female university students (n = 1455) | Urban city, Argentina |
Biggs et al. [42] | ECP | 9/22 participants used ECP as only contraceptive strategy | Qualitative | Women, 15–25 yrs (n = 22) | Urban city; US |
Barbosa et al. [43] | ECP | Repeat ever use: 2–4 times (48%), 5 + times (20% | Quantitative survey | Women, 15–44 yrs (n = 3249) | Urban city, Brazil |
Berglas et al. [44] | ECP | 9/22 participants used ECP as only contraceptive strategy | Qualitative | Women, 15–25 yrs (n = 22) | Urban city; US |
Amorim et al. [45] | ECP | N/A; provider perspectives | Quantitative survey | Paediatric physicians working with adolescents (n = 151) | Amazonas State, Brazil |
SE Asia | |||||
Khan et al. [46] | ECP | N/A; provider perspectives | Quantitative, qualitative | Gynaecologists (n = 71); GPs & specialists (n = 20); stakeholders (n = 11) | Urban cities; India |
Shakya et al. [47] | ECP | N/A; provider perspectives | Quantitative survey | Community pharmacists (n = 227) | Urban districts; Nepal |
Panda et al. [48] | ECP | N/A; provider perspectives | Quantitative survey | Doctors (interns, postgraduate trainees, senior resident doctors) (n = 200) | Urban hospital; India |
Appleton [49] | ECP | Repeat use & main contraception | Qualitative | Women, 20–40 yrs (n = 15) | Urban periphery; India |
Eastern Mediterranean | |||||
Najaji-Sharjabad [50] | ECP | N/A; provider perspectives | Quantitative survey | GPs, midwives & health workers (n = 170) | Urban health centres; Iran |
Europe | |||||
Milosavljevic et al. [51] | ECP | N/A; provider perspectives | Quantitative survey | Gynaecologists (n = 166); community pharmacists (n = 452) | Serbia |
Jambrina et al. [52] | ECP | Repeat ever use: 44% more than once | Surveillance | Women, 16–55 yrs (941 notifications) | Catalonia, Spain |
Western Pacific | |||||
- | - | - | - | - | |